APYX Apyx Medical Corp
Price Chart
Executive Summary
Apyx Medical announced the publication of a retrospective investigator-initiated study in *Plastic and Reconstructive Surgery - Global Open* showing that adding Renuvion (helium plasma RF) to liposuction resulted in statistically significant improvements in patient-reported satisfaction, a >50% lower abdominoplasty rate (30.0% vs. 67.1%), and lower revision rates (12.0% vs. 37.5%) with comparable complication rates. This adds clinical evidence supporting Renuvion's value proposition but does not change the company's financial outlook or near-term revenue trajectory.
Actionable Insight
This is a clinical evidence update, not a financial catalyst. Monitor upcoming quarterly results for any acceleration in Renuvion/AYON adoption that this publication may support. No immediate trading action warranted.
Key Facts
- Study of 113 patients published in PRS Global Open evaluating Renuvion + liposuction vs. liposuction alone
- Renuvion group showed statistically higher satisfaction with reduced excess skin (BodyQ 87.8 vs. 73.8; p=0.03)
- Abdominoplasty rate was >50% lower in Renuvion group (30.0% vs. 67.1%)
- Revision rates significantly lower in Renuvion group (12.0% vs. 37.5%; p=0.038)
- Complication rates similar between groups (2.5% vs. 2.7%)
- No financial guidance, revenue figures, or material financial data provided in the filing
Financial Impact
No financial figures disclosed; clinical publication supports product differentiation but does not quantify revenue impact
Risk Factors
- Retrospective single-surgeon study design limits generalizability
- No financial data or guidance provided in the filing
- Competitive landscape in body contouring remains fragmented
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-016885 |
| Exhibit: ex_962572.htm | 0001437749-26-016885 |
| Document: 0001437749-26-016885-index-headers.html | 0001437749-26-016885 |
| Document: 0001437749-26-016885-index.html | 0001437749-26-016885 |
| Document: 0001437749-26-016885.txt | 0001437749-26-016885 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 21, 2026
22d ago
|
8-K
| $4.13 $3.96 | ▼ −4.12% | ▼ −5.77% | $4.69 (+13.56%) |
|
May 21, 2026
23d ago
|
Press Release
| $4.25 $4.15 | ▼ −2.35% | ▼ −3.95% | $4.69 (+10.35%) |
|
May 14, 2026
4w ago
|
8-K
| $4.36 $4.25 | ▼ −2.52% | ▼ −1.81% | $4.69 (+7.57%) |
|
May 11, 2026
4w ago
|
8-K
| $3.92 $3.87 | ▼ −1.28% | ▼ −1.19% | $4.69 (+19.64%) |
|
Apr 23, 2026
7w ago
|
Press Release
| $3.80 $3.46 | ▼ −8.95% | ▼ −10.43% | $4.69 (+23.42%) |
|
Mar 10, 2026
13w ago
|
Press Release
| $3.45 $3.74 | ▲ +8.41% | ▲ +9.31% | $4.69 (+35.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access